Consequences of increasing resistance to antimicrobial agents

被引:24
作者
Acar, JF [1 ]
Goldstein, FW [1 ]
机构
[1] Fdn Hop St Joseph, Lab Microbiol Med, F-75674 Paris 14, France
关键词
D O I
10.1086/514913
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The correlation between in vitro bacterial susceptibility results and clinical outcome has been debated for many years. Bacterial resistance traits are more significantly correlated with failure of therapy than is an organism's susceptibility to an antimicrobial agent. We review the situations that have supported the clinical relevance of in vitro bacterial resistance. Those situations include: emergence, during therapy, of a new resistance marker not known before; selection of a resistant mutant or acquisition of a resistance gene during therapy; failure to recognize or take into account a new resistance mechanism; and superinfection with resistant bacteria. More information should be obtained in the future by performing studies oriented toward bacteriologically documented clinical failures and by better communication between microbiologists and physicians to correlate the in vitro data with host status, the pharmacokinetics of the antimicrobial agent, and the bacteriologic and clinical outcome.
引用
收藏
页码:S125 / S130
页数:6
相关论文
共 78 条
[1]  
Acar J F, 1970, Antimicrob Agents Chemother (Bethesda), V10, P280
[2]   ACTIVITY OF IMIPENEM ON AEROBIC-BACTERIA [J].
ACAR, JF ;
GOLDSTEIN, FW ;
KITZIS, MD ;
GUTMANN, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 :37-45
[3]  
ACAR JF, 1983, REV INFECT DIS, V5, pS502
[4]   INTERLABORATORY VARIATION OF ANTIBIOGRAMS OF METHICILLIN-RESISTANT AND METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS-AUREUS STRAINS WITH CONVENTIONAL AND COMMERCIAL TESTING SYSTEMS [J].
ALDRIDGE, KE ;
JANNEY, A ;
SANDERS, CV ;
MARIER, RL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1983, 18 (05) :1226-1236
[5]   PROBLEM AND IMPLICATIONS OF CHLORAMPHENICOL RESISTANCE IN TYPHOID BACILLUS [J].
ANDERSON, ES .
JOURNAL OF HYGIENE, 1975, 74 (02) :289-299
[6]  
APPELBAUM PC, 1977, LANCET, V2, P995
[7]  
ASHFORD WA, 1976, LANCET, V2, P657
[8]   EMERGENCE OF CIPROFLOXACIN-RESISTANT PSEUDOMANAS-AERUGINOSA AFTER COMBINED THERAPY WITH CIPROFLOXACIN AND AMIKACIN [J].
AZADIAN, BS ;
BENDIG, JWA ;
SAMSON, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 (06) :771-771
[9]   Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital [J].
Baddour, LM ;
Hicks, DV ;
Tayidi, MM ;
Roberts, SK ;
Walker, E ;
Smith, RJ ;
Sweitzer, DS ;
Herrington, JA ;
Painter, BG .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1995, 1 (03) :219-222
[10]   CEFTRIAXONE THERAPY OF SERIOUS BACTERIAL-INFECTIONS IN ADULTS [J].
BITTNER, MJ ;
DWORZACK, DL ;
PREHEIM, LC ;
TOFTE, RW ;
CROSSLEY, KB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (02) :261-266